ArticleCancers2021

Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma.

Jaume Mora et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.